Skip to content
‹ Back to IndustriesSciences

The Space Race Is Back and Heading to the Public Market

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · AstraBloombergOuter SpacePublic
Share
The Space Race Is Back and Heading to the Public Market

Key takeaways

01

The return of the space race has more companies and investors looking for ways to get into the industry.

02

Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019.

03

The California garage startup, which now occupies a quarter-of-a-million square foot facility…

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

The return of the space race has more companies and investors looking for ways to get into the industry. Astra is the first rocket company since 1990 to announce it will go public, and the latest space SPAC since Virgin Galactic in 2019. The California garage startup, which now occupies a quarter-of-a-million square foot facility in Alameda, is valued at $2 Billion. The company provides rocket launches for $3 Million each, significantly less than that of SpaceX and Rocket Lab. Watch Emily Chang’s report above or read the transcript below.

—

From home garage to full fledged rocket company, Astra is the latest upstart looking to make its name in the space race with big ambitions to ramp up to a rocket launch a day delivering things like satellites, supplies and other cutting edge technology to space within the next four years. To raise capital and fast CEO Chris Kemp plans to capitalize on the SPAC craze, and take the company public this year in a merger with Holicity, run by Billionaire and former telecom mogul Craig McCaw.

Astra would be the latest space back since virgin galactic, which merged with social capital in 2019. Astra, though, wasn’t founded by a billionaire. It started operations in a San Francisco garage with limited funding. The company now designs tests and manufactures a line of small, relatively cheap rockets at its current factory just over the Bay Bridge in Alameda, California. A former Naval base, now home to served as a jet engine research facility and gained popularity as the site of Discovery Channel’s Mythbusters.

The team occupies a quarter of a million square foot research facility where researchers, engineers and scientists can all work under one roof, eliminating the need for complex logistics. In December, successfully launched their 3.2 rocket from the Pacific spaceport complex in Kodiak, Alaska, but nearly missed its orbit target. Kemp has said some minor tweaks should resolve the issue and allow them to fly again this summer.

Spacex is currently the dominant maker of large rockets designed to carry thousands of pounds of payload to orbit. But it comes with cost, charging roughly $60 million per launch. By comparison, rocket lab, founded in New Zealand, and now headquartered in the u.s., starts at around $6 million a launch. Astra is now only capable of smaller payloads than both companies, but will charge just $3 million per launch over the next few years.

The first and last rocket company to go public with Orbital Sciences Corporation back in 1990. It since merged into a subsector of Northrop Grumman. Astra will be the only publicly traded company focused solely on building and launching rockets when it begins trading later this year if Kemp can execute his big vision.

As more and more players join the space race, opportunities will become abundant for investors to enter the arena. But questions still remain around when the industry starts making money. Morgan Stanley believes the global space industry could generate more than a trillion in revenue or more in 2040, up from $350 billion right now, over half the growth coming from satellite broadband technology. And as rocket launches get cheaper and more companies look to commercialize space, profitability may soon be taking off.

*Bloomberg contributed to this article

—

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512